15.30
Neuropace Inc stock is traded at $15.30, with a volume of 143.35K.
It is up +3.31% in the last 24 hours and down -7.10% over the past month.
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.
See More
Previous Close:
$14.81
Open:
$15.08
24h Volume:
143.35K
Relative Volume:
0.76
Market Cap:
$521.63M
Revenue:
$99.53M
Net Income/Loss:
$-21.57M
P/E Ratio:
-23.58
EPS:
-0.6488
Net Cash Flow:
$-9.84M
1W Performance:
-2.86%
1M Performance:
-7.10%
6M Performance:
-4.08%
1Y Performance:
+70.38%
Neuropace Inc Stock (NPCE) Company Profile
Name
Neuropace Inc
Sector
Industry
Phone
(650) 237-2700
Address
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Compare NPCE vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
NPCE
Neuropace Inc
|
15.30 | 504.93M | 99.53M | -21.57M | -9.84M | -0.6488 |
|
ABT
Abbott Laboratories
|
104.49 | 179.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
|
SYK
Stryker Corp
|
336.74 | 126.60B | 25.27B | 3.34B | 4.57B | 8.6334 |
|
MDT
Medtronic Plc
|
84.22 | 106.51B | 36.36B | 4.84B | 5.43B | 3.7261 |
|
BSX
Boston Scientific Corp
|
45.51 | 65.77B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
83.04 | 47.58B | 6.30B | 1.07B | 1.09B | 1.8406 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-25 | Initiated | H.C. Wainwright | Buy |
| Jan-21-25 | Initiated | UBS | Buy |
| Mar-14-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-30-24 | Initiated | Leerink Partners | Outperform |
| Nov-10-23 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-24-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-22-23 | Initiated | Lake Street | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-19-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-07-22 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-11-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-18-21 | Initiated | Robert W. Baird | Outperform |
| May-17-21 | Initiated | JP Morgan | Overweight |
| May-17-21 | Initiated | Morgan Stanley | Overweight |
| May-17-21 | Initiated | SVB Leerink | Outperform |
| May-17-21 | Initiated | Wells Fargo | Overweight |
View All
Neuropace Inc Stock (NPCE) Latest News
Orbimed Advisors LLC Decreases Holdings in NeuroPace, Inc. $NPCE - MarketBeat
Neuropace Inc (NPCE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NeuroPace, Inc. $NPCE Shares Acquired by First Light Asset Management LLC - MarketBeat
NPCE|Neuropace Inc|Price:14.810|Chg%:+0.130 - TradingKey
Neuropace Inc (NPCE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Neuropace Inc (NPCE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
NeuroPace Inc introduces real-time solution to help restore everyday independence - Traders Union
Neuropace Inc (NPCE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Neuropace Inc (NPCE) Income Statement - TradingKey
NeuroPace Inc: Intermountain Health completes 100th RNS System implant for epilepsy patients - Traders Union
Neuropace Inc (NPCE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Mizuho Securities Initiates NeuroPace(NPCE.US) With Buy Rating, Announces Target Price $22 - Moomoo
Mizuho Begins Coverage on NeuroPace (NASDAQ:NPCE) - MarketBeat
NEUROPACE INC : MIZUHO INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $22 - Bitget
Mizuho Securities Initiates Coverage on NeuroPace With Outperform Rating, $22 Price Target - marketscreener.com
Mizuho initiates NeuroPace stock coverage with outperform rating - Investing.com
NeuroPace Inc study reports landmark six month seizure reduction for RNS System patients - Traders Union
Neuropace, Inc. (NPCE) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
NeuroPace (NPCE) Proxy filing Summary - Quartr
(NPCE) Volatility Zones as Tactical Triggers - Stock Traders Daily
NeuroPace (NPCE) Stock Forum and Discussion - Moomoo
Here's why you should retain NeuroPace stock in your portfolio for now - MSN
NeuroPace (NPCE) 25th Annual Needham Virtual Healthcare Conference Summary - Quartr
Neuropace (NPCE) Holds Steady Near Resistance as Trading Volume Remains ModerateValue Area High - dars.gov.et
Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now - Yahoo Finance
NeuroPace (NASDAQ:NPCE) Shares Down 5.8%What's Next? - MarketBeat
NeuroPace, Inc. (NASDAQ:NPCE) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
NeuroPace (NASDAQ:NPCE) Stock Price Up 1.1%What's Next? - MarketBeat
NeuroPace Inc offers free webinar on RNS System for epilepsy patients - Traders Union
At US$17.80, Is It Time To Put NeuroPace, Inc. (NASDAQ:NPCE) On Your Watch List? - simplywall.st
DHR Health pioneers responsive neurostimulation therapy with NeuroPace Inc RNS System in Texas - Traders Union
Neuropace Inc. (NPCE) Q1 2026 Earnings: EPS Surpasses Estimates, Shares GainInvestor Earnings Call - dars.gov.et
Neuropace Inc. (NPCE) Q1 2026 Earnings: EPS Beats Estimates as Loss Narrows, Stock Rises 2.35%Trough Earnings Signal - dars.gov.et
Wall Street analysts see a 41.29% upside in NeuroPace (NPCE): Can the stock really move this high? - MSN
Price to earnings forward of Neuropace, Inc. – NASDAQ:NPCE - TradingView
NPCENeuroPace Inc Website Traffic and Mobile Apps Usage - Finviz
Neuropace Inc. (NPCE) Q1 2026 Earnings: Narrower-than-Expected Loss Lifts SharesBasic EPS Analysis - dars.gov.et
NeuroPace | 4: Statement of changes in beneficial ownership of securities-Director Fischer Frank M - Moomoo
NeuroPace Inc patients see 62 percent median seizure reduction at six months in largest FDA-reviewed study - Traders Union
Price-Driven Insight from (NPCE) for Rule-Based Strategy - Stock Traders Daily
FDA Approves NeuroPace AI Driven Feature For Epilepsy Care - HarianBasis.co
NeuroPace, Inc. (NPCE) Reveals FDA Approval of ECoG Assistant™ - Insider Monkey
NeuroPace, Inc. Actuals & Estimates (NASDAQ:NPCE) - TradingView
NeuroPace (NPCE) CMO has shares withheld to cover RSU tax bill - Stock Titan
NPCE Forecast — Price Target — Prediction for 2027 - TradingView
Neuropace Inc. (NPCE) Q1 2026 Earnings: Narrowed Loss Beats Estimates, Shares Edge HigherReturn On Assets - dars.gov.et
Neuropace Inc (NPCE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Neuropace Inc. (NPCE) Gains on Rising Volume: Support Holds Above $15Fibonacci Extension - dars.gov.et
Form 4 Neuropace Inc For: 22 June By Investing.com - Investing.com Nigeria
[Form 4] NeuroPace Inc Insider Trading Activity - Stock Titan
NeuroPace (NPCE) director granted 789 shares as quarterly fee award - Stock Titan
Neuropace Inc Stock (NPCE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):